Eli Lilly: In type 2 diabetes trials, Orforglipron outperforms Semaglutide in both blood sugar control and weight loss.
Show original
Glonghui, February 26th｜Eli Lilly stated that in type 2 diabetes trials, its oral GLP-1 drug Orforglipron outperformed Novo Nordisk's oral semaglutide in both blood sugar control and weight loss. Applications for Orforglipron have been submitted to regulatory agencies in more than 40 countries, and the company expects to initiate the obesity indication approval process in the United States in the second quarter of 2026.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
US-Iran Conflict Erupts, Bank of Japan Suggests No Rate Hike in March
BlockBeats•2026/03/02 05:35
Australian stocks closed up 0.03%, reaching a record high at close
格隆汇•2026/03/02 05:26
Trending news
MoreCrypto prices
More
Bitcoin
BTC
$66,757.86
-1.11%
Ethereum
ETH
$1,971
-2.48%
Tether USDt
USDT
$1
+0.01%
BNB
BNB
$623.19
-1.10%
XRP
XRP
$1.36
-3.70%
USDC
USDC
$1
+0.01%
Solana
SOL
$84.26
-4.15%
TRON
TRX
$0.2811
-0.42%
Dogecoin
DOGE
$0.09302
-3.41%
Cardano
ADA
$0.2752
-3.81%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now